Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

  • Revenue in USD (TTM)46.74bn
  • Net income in USD6.68bn
  • Incorporated1933
  • Employees32.20k
  • Location
    Bristol-Myers Squibb Co430 E. 29Th Street, 14 FloorNEW YORK 10016United StatesUSA
  • Phone+1 (212) 546-4000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.bms.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BMY:NYQ since
Turning Point Therapeutics IncDeal completed03 Jun 202203 Jun 2022Deal completed7.63%4.08bn
Data delayed at least 15 minutes, as of Dec 05 2022 20:32 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Gilead Sciences, Inc.27.14bn3.33bn111.67bn14.40k33.675.3020.614.122.642.6421.5216.810.41864.396.081,884,445.005.108.356.0710.0274.6279.5612.1922.221.165.860.54558.7610.60-2.124,960.98-14.34-4.999.07
Amgen, Inc.26.33bn6.84bn152.34bn24.20k22.8741.7014.955.7912.4812.4848.096.850.40921.435.221,088,017.0010.6211.0713.7413.4075.7879.2925.9630.881.357.700.913849.282.182.47-18.87-5.261.0111.97
Bristol-Myers Squibb Co46.74bn6.68bn172.50bn32.20k26.455.2710.133.693.073.0721.5315.380.44714.655.721,451,491.006.402.677.943.2978.9174.1814.326.541.314.490.5443163.849.0919.01177.589.43-4.355.22
Data as of Dec 05 2022. Currency figures normalised to Bristol-Myers Squibb Co's reporting currency: US Dollar USD

Institutional shareholders

32.02%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2022190.97m8.98%
BlackRock Fund Advisorsas of 30 Sep 2022112.66m5.30%
SSgA Funds Management, Inc.as of 30 Sep 202292.33m4.34%
JPMorgan Investment Management, Inc.as of 30 Sep 202263.34m2.98%
Capital Research & Management Co. (International Investors)as of 30 Sep 202252.40m2.46%
Fidelity Management & Research Co. LLCas of 30 Sep 202251.60m2.43%
Geode Capital Management LLCas of 30 Sep 202239.15m1.84%
Wellington Management Co. LLPas of 30 Sep 202233.39m1.57%
Norges Bank Investment Managementas of 31 Dec 202122.68m1.07%
Managed Account Advisors LLCas of 30 Sep 202222.27m1.05%
More ▼
Data from 31 Dec 2021 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.